Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer ...

Evan Y. Yu, MD, discusses how individualized first-line systemic therapy selection for metastatic hormone-sensitive prostate ...

达罗他胺 首次于 2019 年在美国获批上市，用于 去势抵抗性前列腺癌的一线治疗 ，2021 年同适应症在中国获批上市， 2023 年在中国获批新适应症， 与 ADT 和多西他赛联合使用 ，用于 激素依赖性前列腺癌的一线治疗 。

1月8日，拜耳公司宣布，诺倍戈（达罗他胺）联合雄激素剥夺疗法（ADT）治疗转移性激素敏感性前列腺癌（mHSPC）成年患者的新适应症申请已获国家药品监督管理局（NMPA）药品审评中心（CDE）受理。国家药品监督管理局药品审评中心诺倍戈是口服新一代雄激素 ...

The sNDA is seeking label expansion of Nubeqa in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...

Orion's collaboration partner Bayer submits application in China for third indication of darolutamide ...

Darolutamide + ADT in combination with docetaxel is to be used to treat patients with metastatic hormone-sensitive prostate cancer (mHSPC) and will be immediately available in England for eligible ...

Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, January 8, 2 ...

1 月 7 日，拜耳宣布已向 CDE 提交口服雄激素受体抑制剂（ARi）达罗他胺的上市申请，与雄激素剥夺疗法（ADT）联合用药，用于治疗转移性激素敏感性前列腺癌（mHSPC）患者。这是该药在中国申报的第 3 ...